This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Roger K. Cady, MD; Jeanette K. Wendt, MD; John R. Kirchner, MD; Joseph D. Sargent, MD; John F. Rothrock; Harold Skaggs, Jr, MD

JAMA. 1991;265(21):2831-2835.

Abstract
Sumatriptan succinate, a 5-HT_1D receptor agonist, constricts human cranial arteries. Two parallel-group trials for treatment of acute migraines were conducted in the United States. Adult patients were randomized and given either 6 mg of sumatriptan succinate subcutaneously (n = 734) or placebo (n = 370). At 1 hour, sumatriptan was significantly more effective than placebo in reducing moderate or severe headache pain to mild or no pain (70% vs 22%), in completely relieving headaches (49% vs 9%), and in improving clinical disability (76% vs 34%). Sumatriptan also reduced nausea and photophobia significantly better than placebo. Patients with residual migraines received another injection; those who had originally received sumatriptan received either a second active injection (n = 187) or placebo (n = 178), while those who had received placebo received a second placebo injection (n = 335). Statistical evidence for benefit of second sumatriptan injection is absent. Adverse events associated with sumatriptan were tingling, dizziness, warm-hot sensations, and injection-site reactions. Sumatriptan is effective and well tolerated in patients with acute migraine.

(JAMA. 1991;265:2831-2835)

Author Affiliations
From the Shealy Institute for Comprehensive Health Care, Springfield, Mo (Dr Cady); Department of Neurology, Health Science Center, University of Arizona, Tucson (Dr Wendt); the Migraine Treatment Clinic, Omaha, Neb (Dr Kirchner); Headache and Internal Medicine Research Center, Menninger, Topeka, Kan (Dr Sargent); Department of Neurology, University of California at San Diego Medical Center (Dr Rothrock); Neurology Section, Center for Clinical Research, Austin, Tex (Dr Skaggs); on behalf of the US Sumatriptan Research Group.; Dr Cady owns stock in Glaxo Pharmaceuticals Inc.

Footnotes
Reprint requests to Shealy Institute for Comprehensive Health Care, 1328 E Evergreen St, Springfield, MO 65803 (Dr Cady).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines
Friedman et al.
Neurology 2005;64:463-468.
ABSTRACT | FULL TEXT  

Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache
Snow et al.
ANN INTERN MED 2002;137:840-849.
ABSTRACT | FULL TEXT  

Headache Evaluation and Treatment by Primary Care Physicians in an Emergency Department in the Era of Triptans
Maizels
Arch Intern Med 2001;161:1969-1973.
ABSTRACT | FULL TEXT  

A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents
Winner et al.
Pediatrics 2000;106:989-997.
ABSTRACT | FULL TEXT  

Migraine: pharmacotherapy in the emergency department
Kelly
Emerg. Med. J. 2000;17:241-245.
ABSTRACT | FULL TEXT  

Changes in Resource Use and Outcomes for Patients With Migraine Treated With Sumatriptan: A Managed Care Perspective
Lofland et al.
Arch Intern Med 1999;159:857-863.
ABSTRACT | FULL TEXT  

Multiple-Attack Efficacy and Tolerability of Sumatriptan Nasal Spray in the Treatment of Migraine
Diamond et al.
Arch Fam Med 1998;7:234-240.
ABSTRACT | FULL TEXT  

Sumatriptan Injection Reduces Productivity Loss During a Migraine Attack: Results of a Double-blind, Placebo-Controlled Trial
Cady et al.
Arch Intern Med 1998;158:1013-1018.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain: Three Double-blind, Randomized, Placebo-Controlled Trials
Lipton et al.
Arch Neurol 1998;55:210-217.
ABSTRACT | FULL TEXT  

Acute Treatment of Migraine With Dihydroergotamine Nasal Spray
Gallagher and Dihydroergotamine Working Group
Arch Neurol 1996;53:1285-1291.
ABSTRACT  

Oral Sumatriptan in the Treatment of Recurrent Headache
Cady et al.
Arch Fam Med 1994;3:766-772.
ABSTRACT  

Drug points: Is there a problem with long term use of sumatriptan in acute migraine?
Osborne et al.
BMJ 1994;308:113-113.
FULL TEXT  

Drug Therapy of Migraine
Welch
NEJM 1993;329:1476-1483.
FULL TEXT  

Pharmacologic Therapy, Nondrug Therapy, and Counseling Are Keys to Effective Migraine Management
Sheftell
Arch Fam Med 1993;2:874-879.
ABSTRACT  

Dose Ranging Efficacy and Safety of Subcutaneous Sumatriptan in the Acute Treatment of Migraine
Mathew et al.
Arch Neurol 1992;49:1271-1276.
ABSTRACT  

Neurology
Joynt
JAMA 1992;268:380-382.
ABSTRACT  

Subcutaneous Sumatriptan in Acute Migraine
Korenfeld
JAMA 1991;266:2703-2703.
ABSTRACT  

Subcutaneous Sumatriptan in Acute Migraine
Tfelt-Hansen et al.
JAMA 1991;266:2703-2703.
ABSTRACT  

SUMATRIPTAN FOR ACUTE MIGRAINE
JWatch General 1991;1991:2-2.
FULL TEXT